SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Muller D, Agrawal R, Arntz H-R. How sudden is sudden cardiac death? Circulation 2006; 114: 114650.
  • 2
    Wannamethee G, Shaper AG, Macfarlane PW, Walker M. Risk factors for sudden cardiac death in middle-aged British men. Circulation 1995; 91: 174956.
  • 3
    Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 101322.
  • 4
    Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, Van Der Lei J, De Graeff PA, Kingma JH, Stricker BH. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005; 26: 200712.
  • 5
    Straus SMJM, Bleumink GS, Dieleman JP, Van Der Lei J, 't Jong GW, Kingma JH, Sturkenboom MCJM, Stricker BHC. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004; 164: 12937.
  • 6
    Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 11616.
  • 7
    Gill SS, Bronskill SE, Normand ST, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrman N, Gurwitz JH, Rochon PA. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146: 77586.
  • 8
    Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 108996.
  • 9
    Centre for Education and Research on Therapeutics. QT drug lists by risk groups. Available at http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm (last accessed 4 August 2009).
  • 10
    Hinkle LE, Thaler HT. Clinical classification of cardiac deaths. Circulation 1982; 65: 45764.
  • 11
    Home Office. Reforming the Coroner and death certification service: a position paper. Home Office. March 2004. Available at http://www.archive2.official-documents.co.uk/document/cm61/6159/6159.pdf (last accessed 3 August 2009).
  • 12
    British National formulary, 55: 179276. London: BMJ Group and RPS Publishing, 2008.
  • 13
    Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002; 180: 51522.
  • 14
    Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 177482.
  • 15
    Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002; 450: 3741.
  • 16
    Lindborg SR, Beasley CM, Alaka K, Taylor CC. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res 2003; 119: 11323.
  • 17
    Fossa AA, Wisialowski T, Wolfgang E, Wang E, Avery M, Raunig DL, Fermini B. Differential effect of HERG blocking agents on cardiac alternans in the guinea pig. Eur J Pharmacol 2004; 486: 20921.
  • 18
    Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedrone C, Mor V, Bernabei R. Conventional and atypical antipsychotics and the risk of hospitalisation for ventricular arrhythmias or cardiac arrest. Arch Intern Med 2005; 165: 696701.
  • 19
    Jo SH, Youm JB, Lee CO, Earm YE, Ho WK. Blockade of the HERG human cardiac (K+) channel by the antidepressant drug amitryptiline. Br J Pharmacol 2000; 129: 147480.
  • 20
    Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23: 5877.
  • 21
    Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75: 23441.
  • 22
    Drolet B, Yang T, Daleau P, Roden DM, Turgeon J. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol 2003; 41: 9347.
  • 23
    Morissette P, Hreiche R, Mallet L, Vo D, Knaus EE, Turgeon J. Olanzapine prolongs cardiac repolarisation by blocking the rapid component of the delayed rectifier potassium current. J Psychopharmacol 2007; 21: 73541.
  • 24
    Lee S-Y, Kim Y-J, Kim K-T, Choe H, Jo S-H. Blockade of HERG human K channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol 2006; 149: 4819.
  • 25
    Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 233541.
  • 26
    Hollis J, Grayson D, Forrester L, Brodaty H, Touyz S, Cumming R. Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 2007; 15: 93241.
  • 27
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 193443.
  • 28
    Hennessey S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, Glasser DB, Morrison MF, Strom BL. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325: 1070.
  • 29
    Ray WA, Chung CP, Murray KT, Hall K, Stein M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 22535.
  • 30
    Whang W, Kubzansky LD, Kawachi I, Rexrode KM, Kroenke CH, Glynn RJ, Garan H, Albert CM. Depression and risk of sudden cardiac death and coronary heart disease in women. J Am Coll Cardiol 2009; 53: 9508.
  • 31
    Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24: 629.
  • 32
    Baker B, Dorian P, Sander P, Shapiro C, Schell C, Mitchell J, Irvine MJ. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 1997; 17: 1521.
  • 33
    Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999; 19: 40715.
  • 34
    Steinberg MI, Smallwood JK, Holland DR, Bymaster FP, Bemis KG. Hemodynamic and electrocardiographic effects of fluoxetine and its major metabolite, norfluoxetine, in anesthetised dogs. Toxicol Appl Pharmacol 1986; 82: 709.
  • 35
    Pacher P, Magyar J, Szigligeti P, Banyasz T, Pankucsi C, Korom Z, Ungvari Z, Kecskemeti V, Nanasi PP. Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 6773.
  • 36
    Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, Reynolds CF. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006; 14: 796802.
  • 37
    Duncan RS, McPate MJ, Ridley JM, Gao J, James AF, Leishman DJ, Leaney JL, Witchel HJ, Hancox JC. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol 2007; 74: 42537.
  • 38
    Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 2003; 139: 88798.
  • 39
    Hancox JC, Mitcheson JS. Combined hERG channel inhibition and disruption of trafficking in induced long QT syndrome by fluoxetine: a case study in cardiac safety pharmacology. Br J Pharmacol 2006; 149: 4579.
  • 40
    Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 2002; 512: 5966.
  • 41
    Fossa AA, Gorczyca W, Wisialowski T, Yasgar A, Wang E, Crimin K, Volberg W, Zhou J. Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. J Pharmacol Toxicol Methods 2007; 55: 7885.
  • 42
    Bowker TJ, Wood DA, Davies MJ, Sheppard MN, Cary NRB, Burton JDK, Chambers DR, Dawling S, Hobson HL, Pyke SDM, Riemersma RA, Thompson SG. Sudden unexpected cardiac or unexplained death in England: a national survey. Q J Med 2003; 96: 26979.
  • 43
    Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden cardiac death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation 2009; 119: 66370.
  • 44
    Bender R, Lange S. Adjusting for multiple testing – when and how? J Clin Epidemiol 2001; 54: 3439.
  • 45
    Chambers AS, Allen JJ. Sex differences in cardiac vagal control in a depressed sample: implications for differential cardiovascular mortality. Biol Psychol 2007; 75: 325.
  • 46
    Watkins LL, Blumenthal JA, Davidson JR, Babyak MA, McCants CB Jr, Sketch HM Jr. Phobic anxiety, depression, and risk of ventricular arrhythmias in patients with coronary heart disease. Psychosom Med 2006; 68: 6516.